Rapid7, Inc. provides cybersecurity software and services under the Rapid7, Nexpose, and Metasploit brand names. The company offers Rapid7 Insight Agent, a software-based agent that is used on assets across on-premises and cloud environments to centralize and monitor data on company's platform; Rapid7 Insight Network Sensor that analyzes raw end-to-end network traffic to increase visibility into user activity, pinpoint real threats, and investigations; Rapid7 Cloud Event Data Harvesting that offers visibility into changes made to cloud resources; and third-party integrations and ecosystem, as well as orchestration and automation solutions. It also offers various platforms, including Rapid7 managed threat complete consisting of managed detection response that delivers end-to-end threat detection and response; Rapid7 threat complete consisting of InsightIDR, a security information and event management, and extended detection and response solution; Incident Response Services to prepare and respond to potential breaches; Exposure Command, an exposure management to provide attack surface visibility; and Exposure Command Advanced to provide strong security for workloads leveraging real-time visibility, identity analysis, and automated remediation. In addition, the company provides Surface Command, a Cyber Asset Attack Service Management solution to detect and prioritize security issues from endpoint to cloud; Vector Command, a continuous red-teaming service that validates the external attack surface exposures and tests defenses; InsightCloudSec, a cloud risk and compliance management solution; InsightAppSec, a dynamic application security testing tool; and InsightVM, a vulnerability management solution that provides visibility across on-premise and remote endpoints for security. Further, it offers offloads day-to-day, advisory, and professional services. The company was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Rapid7 Inc.

In a report released on January 16, Matthew Hedberg from RBC Capital maintained a Hold rating on Rapid7, with a price target of $16.00. The company...

Rapid7 (RPD) Receives a Hold from RBC Capital

In a report released on January 5, Geoff Meacham from Citi reiterated a Buy rating on Royalty Pharma, with a price target of $48.00. According to T...

Citi Sticks to Their Buy Rating for Royalty Pharma (RPRX)

In a report released today, Saket Kalia from Barclays downgraded Rapid7 to a Sell, with a price target of $15.00. According to TipRanks, Kalia is a...

Current Quarter	$0.04	Next Quarter	$0.16
Current Year	$0.6	Next Year	$0.66
QoQ Growth	+300.0%	YoY Growth	+10.0%
3Y EPS CAGR	+29.2%	Target Price	$18.40
Consensus	Buy	Upside	+55.9%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RPD	$11.80	-1.01%	1.28M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RPD	$11.80	-1.0%	1.28M
3
4
5
6

RPD

RPD

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Rapid7 Inc. Data in Excel

Get Rapid7 Inc. Data in Excel